Indexing hint: Randomized controlled trial · 2021
Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients.
Ghanizada et al. 2021Annals of neurologycited by 92
PMID 33772845PMC8486152DOI 10.1002/ana.26072PUB-33772845
Trial · Interventional
Not yet recruitingNot applicableRegistry dataThis trial does not test a peptide that PepBank tracks.
Denmark
1 trial · 1 not yet recruiting
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.
Experimental
Amylin
Pramlintide (Amylin) will be administered by intravenous infusion.
Placebo comparator
Placebo
Placebo (isotonic saline) will be administered by intravenous infusion.
Outcomes the sponsor listed as primary.
Incidence of migraine attacks without aura
Time frame · 12 hours
The difference in the incidence of migraine attacks without aura between pramlintide and placebo during the 12-hour observational period after infusion start.
Headache intensity scores
Time frame · 12 hours
The secondary outcome is the difference in the area under the curve (AUC) for median headache intensity scores between pramlintide and placebo during the 12-hour observational period after infusion start.
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
A trial that is still running, or that stopped early, may post results later.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies that cite this trial.
2 studies on this page
Indexing hint: Randomized controlled trial · 2021
Ghanizada et al. 2021Annals of neurologycited by 92
PMID 33772845PMC8486152DOI 10.1002/ana.26072PUB-33772845
Indexing hint: Randomized controlled trial · 2010
Asmar et al. 2010The Journal of clinical endocrinology and metabolismcited by 34
PMID 20194711DOI 10.1210/jc.2009-2133PUB-20194711
1 study on this page
Indexing hint: Review · 2015
Hay et al. 2015Pharmacological reviewscited by 318
PMID 26071095DOI 10.1124/pr.115.010629PUB-26071095
Who could join, as posted.
PepBank is a research reference. Talk to a doctor before you use any peptide.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated